Zifo: Fragmented CMC Data Creates 'Billion-Dollar Bottleneck' in Biopharma
Cambridge, Mass. – September 30, 2026 -- Biopharma companies are losing time and money to a recurring pattern of disconnected experiments and manual data reconciliation that Zifo calls the 'DMTA doom loop,' according to a new position paper from the scientific informatics firm.
Zifo identifies a structural flaw in the Design-Make-Test-Analyse process
The paper, titled 'The Billion-Dollar Bottleneck: Why CMC Is Strangling the Biopharma Pipeline,' argues that the DMTA cycle used in chemistry, manufacturing and controls (CMC) work is forced into a rigid, linear execution model rather than adapting to what the science actually requires. Zifo says evidence in many CMC environments is scattered across scientific applications, instruments, spreadsheets, PDFs, batch records and individual expertise, forcing scientists to reconstruct experimental histories and decision reasoning before they can even begin new work.
